Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2016

Open Access 01-12-2016 | Erratum

Erratum to: ‘Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia’

Authors: Chien-Hung Yeh, Xue Tao Bai, Ramona Moles, Lee Ratner, Thomas A. Waldmann, Toshiki Watanabe, Christophe Nicot

Published in: Molecular Cancer | Issue 1/2016

Login to get access

Excerpt

Unfortunately, the original version of this article [1] contained an error. The author Toshiki Watanabe’s first name and surname were placed in the wrong order. Here we have included them in the correct order. There will be an update to go alongside this erratum in correcting this error. …
Literature
1.
Yeh C-H, Bai XT, Moles R, Ratner L, Waldmann TA, Watanabe T, et al. Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia. Mol Cancer. 2016;15:15.CrossRefPubMedPubMedCentral
Metadata
Title
Erratum to: ‘Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia’
Authors
Chien-Hung Yeh
Xue Tao Bai
Ramona Moles
Lee Ratner
Thomas A. Waldmann
Toshiki Watanabe
Christophe Nicot
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2016
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-016-0504-8

Other articles of this Issue 1/2016

Molecular Cancer 1/2016 Go to the issue

Research

PKM2 promotes tumor angiogenesis by regulating HIF-1α through NF-κB activation

Research

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells

Research

Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model

Research

MiR-204 silencing in intraepithelial to invasive cutaneous squamous cell carcinoma progression

Research

Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells – evidence for a role in hepatocellular carcinoma growth in vivo

Review

Detection of cancer cells using SapC-DOPS nanovesicles
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits